DOSTARLIMAB vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Compare DOSTARLIMAB (Jemperli) and PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH (KEYTRUDA QLEX) — clinical data, side effects, and patient experiences.

DOSTARLIMAB

Jemperli · Immune Checkpoint Inhibitor

How it works

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of ...

Approved for

1 INDICATIONS AND USAGE JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel

followed by JEMPERLI as a single agent

as determined by an FDA-approved test

that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1

IntravenousTablet

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

KEYTRUDA QLEX, Keytruda · Immune Checkpoint Inhibitor

How it works

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of...

Approved for

1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab

a programmed death receptor-1 (PD-1)-blocking antibody

and berahyaluronidase alfa

an endoglycosidase

SubcutaneousTablet

Quick Comparison

DOSTARLIMABPEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Drug Class

Immune Checkpoint Inhibitor

Route

Intravenous

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

DOSTARLIMAB

Rash

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Joint Pain

1-10%

Fever

1-10%

Condition Worsened

0.1-1%

Nausea

0.1-1%

Shortness of Breath

0.1-1%

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Diarrhea

1-10%

Fatigue

1-10%

Fever

1-10%

Rash

1-10%

Nausea

1-10%

Decreased Appetite

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

FDA Warnings

DOSTARLIMAB

5 WARNINGS AND PRECAUTIONS • Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune‑mediated pneumonitis, immune-mediated colitis, immune‑mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune‑mediated dermatologic adverse reactions, and solid organ transplant rejection
2 ) • Complications of allogeneic hematopoietic stem cell transplantation (HSCT): Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD‑1/PD-L1–blocking antibody
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception
1 Severe and Fatal Immune-Mediated Adverse Reactions JEMPERLI is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance, and inducing immune-mediated adverse reactions

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

5 WARNINGS AND PRECAUTIONS Immune-Mediated Adverse Reactions ( 5
1 ) Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection
2 ) Complications of Allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody
Advise females of reproductive potential of the potential risk to a fetus and to use effective method of contraception

Community Sentiment Analysis

Based on 8 Reddit discussions

DOSTARLIMAB

75%

positive

8 threads

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

positive

0 threads

Community-Reported Side Effects

% of discussions mentioning each side effect

Community Discussions

8 Reddit threads analysed for DOSTARLIMAB

Overall Sentiment

Positive

Comparison Threads

Avg Post Score

19 upvotes

Most discussed side effects in community

Sexual Dysfunction (1)

Vision Changes (1)

Fatigue (1)

Weight Loss (1)

Patient Experiences (r/pharmacy, r/AskDocs & more)

This Is Where Our Eyes Belong

Just want to re-iterate. I'm not a prophet. Not a teacher. I don't speak in front of live audiences. I have zero out of body experiences. No dreams. It's just me here. I'm like you, studying it. Everything I say is how I interpret it. If you're reading this, then, it's up to you to balance,

r/LeronLimab_Times41143y ago

The Timeline and The Connections

Here is another long look at the past couple of years. Take it as you may. This is a discussion, not a declaration of truth. This is an interpretation of what we know via statement and a hypothetical assembly of those words into what may be behind them. Let's try to put it together the way it cou

r/Livimmune32362y ago

Sexual Dysfunction

Vision Changes

In Preparation for the R&D Update

I copied here for convenience, the PR of 11/22/22: # "CytoDyn to Host R&D Update on Wednesday, December 7, 2022 VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- **CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist w

r/LeronLimab_Times30323y ago

Divide And Conquer

I know I put out a post yesterday, but for the sake of consistency, I did not want a Sunday to pass without a signature post. I'm not yet ready to break that trend. So here you go. But, I am pleased to see more and more posters. In [last week's post](https://www.reddit.com/r/Livimmune/comments/1g

r/Livimmune26401y ago

Fatigue

Working during chemo

I’m starting carboplatin/paclitaxel and dostarlimab for endometrial cancer on Feb 18th. It will be 6 infusions every three weeks with the immunotherapy continuing every 6 weeks for 3 years if all goes as planned. My oncologist stated that most of her patients continue to work through chemo. I’m a fi

r/Chemotherapy10203mo ago

Dostarlimab/Jemperli

Hi Guys, I am Jon 39 from Germany. I was diagnosed with Lynch syndrome with an advanced rectal tumor at the age of 21. Cancer has been with my family for generations; my grandfather died of colon cancer at the age of 36 and my mother died at the age of 57. Since my diagnosis in 2007 and neoadjuvant

r/lynchsyndrome9371y ago

FDA announces next round of priority review vouchers

The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. The announcement came as the Trump administration unveiled agreements with E

r/WhatTrumpHasDone315mo ago

Weight Loss

My take on Acrivon Therapeutics ($ACRV)

# Pipeline Development Acrivon Therapeutics specializes in oncology through its Acrivon Predictive Precision Proteomics (AP3) platform, which identifies compound-specific protein signatures to predict patient response. While the company positions AP3 as a repeatable discovery engine, it currently re

r/biotech_stocks222mo ago

Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.

Community Discussions

No community discussions found for PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH yet.

DOSTARLIMAB vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH: What You Should Know

Key Differences

Both DOSTARLIMAB and PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH belong to the Immune Checkpoint Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. DOSTARLIMAB is administered via Intravenous, whereas PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH uses Subcutaneous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

DOSTARLIMAB carries 4 FDA warnings. PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

CEMIPLIMAB-RWLC vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH→AVELUMAB vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH→CEMIPLIMAB-RWLC vs DOSTARLIMAB→AVELUMAB vs DOSTARLIMAB→Nivolumab vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH→DOSTARLIMAB vs Nivolumab→

Loading comparison data...

DOSTARLIMAB vs PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Compare DOSTARLIMAB (Jemperli) and PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH (KEYTRUDA QLEX) — clinical data, side effects, and patient experiences.

DOSTARLIMAB

Jemperli · Immune Checkpoint Inhibitor

How it works

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of ...

Approved for

1 INDICATIONS AND USAGE JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel

followed by JEMPERLI as a single agent

as determined by an FDA-approved test

that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1

IntravenousTablet

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

KEYTRUDA QLEX, Keytruda · Immune Checkpoint Inhibitor

How it works

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of...

Approved for

1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab

a programmed death receptor-1 (PD-1)-blocking antibody

and berahyaluronidase alfa

an endoglycosidase

SubcutaneousTablet

Quick Comparison

DOSTARLIMABPEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Drug Class

Immune Checkpoint Inhibitor

Route

Intravenous

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

DOSTARLIMAB

Rash

1-10%

Fatigue

1-10%

Diarrhea

1-10%

Joint Pain

1-10%

Fever

1-10%

Condition Worsened

0.1-1%

Nausea

0.1-1%

Shortness of Breath

0.1-1%

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

Diarrhea

1-10%

Fatigue

1-10%

Fever

1-10%

Rash

1-10%

Nausea

1-10%

Decreased Appetite

1-10%

High Blood Pressure

0.1-1%

Weakness

0.1-1%

FDA Warnings

DOSTARLIMAB

5 WARNINGS AND PRECAUTIONS • Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune‑mediated pneumonitis, immune-mediated colitis, immune‑mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune‑mediated dermatologic adverse reactions, and solid organ transplant rejection
2 ) • Complications of allogeneic hematopoietic stem cell transplantation (HSCT): Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD‑1/PD-L1–blocking antibody
Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception
1 Severe and Fatal Immune-Mediated Adverse Reactions JEMPERLI is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance, and inducing immune-mediated adverse reactions

PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH

5 WARNINGS AND PRECAUTIONS Immune-Mediated Adverse Reactions ( 5
1 ) Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection
2 ) Complications of Allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody
Advise females of reproductive potential of the potential risk to a fetus and to use effective method of contraception